| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.ASN.0000131523.17045.56 |
| P8608 | Fatcat ID | release_gwdhqmlv5ncy5ngrifuc4zb2ym |
| P698 | PubMed publication ID | 15213276 |
| P5875 | ResearchGate publication ID | 8495524 |
| P2093 | author name string | Angela Cooper | |
| Iain C Macdougall | |||
| Ashraf Mikhail | |||
| D Michael Kemeny | |||
| Mark W Lethbridge | |||
| P433 | issue | 7 | |
| P921 | main subject | patient | Q181600 |
| erythropoietin | Q218706 | ||
| pentoxifylline | Q416331 | ||
| P304 | page(s) | 1877-1882 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | |
| P478 | volume | 15 |
| Q33631006 | Administration of pentoxifylline to improve anemia of hemodialysis patients |
| Q55509823 | An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. |
| Q35653263 | Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients |
| Q63681899 | Clinical Practice Guidelines for supplemental therapies and issues |
| Q64258216 | Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients |
| Q37880158 | Diagnosis and management of anaemia of chronic disease: current status |
| Q35222407 | Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure |
| Q41879242 | Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients |
| Q36884461 | Erythropoiesis-stimulating agent hyporesponsiveness. |
| Q34606348 | Erythropoietin after a century of research: younger than ever |
| Q37257340 | Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study |
| Q38114162 | How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements |
| Q36310894 | Hyporesponsiveness to erythropoietic therapy due to chronic inflammation |
| Q46003419 | Immunological mechanisms of pentoxifylline in chronic heart failure. |
| Q37492328 | Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness |
| Q34023543 | Inflammation in diabetic kidney disease |
| Q89658327 | Inflammatory Targets in Diabetic Nephropathy |
| Q35133177 | Inflammatory cytokines in diabetic nephropathy. |
| Q37871339 | Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. |
| Q51738037 | Intestinal adsorption of uraemic toxins: a new strategy for anaemia management? |
| Q34255473 | Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. |
| Q54977897 | Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy. |
| Q33356816 | Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial |
| Q41663598 | Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease |
| Q26799740 | Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis |
| Q64095815 | Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons |
| Q35544336 | Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase |
| Q36271076 | Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis |
| Q37657448 | Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients |
| Q57684047 | The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial |
| Q40746655 | Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients |
Search more.